SLSN
SLSN
Solesence, Inc. Common StockIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $14.6M ▼ | $4.15M ▲ | $-1.12M ▼ | -7.67% ▼ | $-0.02 ▼ | $-556K ▼ |
| Q2-2025 | $20.36M ▲ | $3.97M ▲ | $2.67M ▲ | 13.1% ▲ | $0.04 ▲ | $3.37M ▲ |
| Q1-2025 | $14.63M ▲ | $3.13M ▲ | $80K ▲ | 0.55% ▲ | $0 ▲ | $482K ▲ |
| Q4-2024 | $12.57M ▼ | $2.99M ▲ | $-558K ▼ | -4.44% ▼ | $-0.01 ▼ | $5K ▼ |
| Q3-2024 | $16.87M | $2.9M | $3.04M | 18.05% | $0.04 | $3.43M |
What's going well?
R&D spending is steady, and there are no unusual charges distorting results. The company is still investing in its future and hasn't taken on excessive debt.
What's concerning?
Revenue dropped 28%, margins are shrinking, and the company is now losing money after being profitable last quarter. Operating expenses are rising despite falling sales, raising concerns about cost control and business momentum.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $429K ▼ | $53.99M ▼ | $36.76M ▼ | $17.23M ▼ |
| Q2-2025 | $4.11M ▲ | $59.96M ▲ | $41.77M ▼ | $18.19M ▲ |
| Q1-2025 | $1.82M ▲ | $57.02M ▲ | $41.86M ▲ | $15.16M ▲ |
| Q4-2024 | $1.41M ▼ | $50M ▲ | $35.06M ▲ | $14.95M ▼ |
| Q3-2024 | $2.92M | $48.05M | $32.88M | $15.17M |
What's financially strong about this company?
The company has no goodwill or intangibles, so its assets are mostly real and tangible. Debt fell slightly, and working capital needs improved as inventory and receivables declined.
What are the financial risks or weaknesses?
Cash has dropped to a dangerously low level, and the company has a heavy debt load compared to its equity. Retained losses are large, and equity is shrinking, which means the company may need to raise money soon.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.12M ▼ | $-2.51M ▼ | $-418K ▲ | $-750K ▼ | $-3.68M ▼ | $-2.93M ▼ |
| Q2-2025 | $2.67M ▲ | $-654K ▲ | $-1.41M ▼ | $4.35M ▼ | $2.29M ▲ | $-654K ▲ |
| Q1-2025 | $80K ▲ | $-7.22M ▼ | $133K ▲ | $7.5M ▲ | $408K ▲ | $-7.22M ▼ |
| Q4-2024 | $-558K ▼ | $2.19M ▼ | $-2.59M ▼ | $-1.11M ▲ | $-1.52M ▼ | $-404K ▼ |
| Q3-2024 | $3.05M | $4.2M | $-1.4M | $-2.23M | $567K | $2.8M |
What's strong about this company's cash flow?
Receivables and inventory were managed well this quarter, bringing in some cash. No new shares were issued, so existing shareholders weren't diluted.
What are the cash flow concerns?
Operating cash burn jumped to $2.51 million, and free cash flow was deeply negative. Cash reserves are nearly gone, and the company is highly dependent on outside funding to survive.
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
Advanced Materials | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Consumer Products | $0 ▲ | $0 ▲ | $20.00M ▲ | $10.00M ▼ |
Personal Care ingredients | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Solesence | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q3-2024 | Q4-2024 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
NonUS | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Q3 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Solesence, Inc. Common Stock's financial evolution and strategic trajectory over the past five years.
Solesence combines strong recent revenue growth with clear technological differentiation in a high-interest segment of beauty. It has shown that it can swing back to profitability and positive operating cash, while its patent-backed platforms, vertical integration, and regulatory expertise create real barriers to entry. The balance sheet has strengthened with more equity and lower leverage than at its recent peak, and the business model benefits from a flexible, partnership-driven approach to serving multiple brands.
The company’s financial history is short and volatile, with two years of losses, negative retained earnings, and mostly negative free cash flow. It still relies on debt, leases, and external capital to fund its growth and heavy investment. Liquidity is manageable but not abundant, with a lot of working capital tied up in inventory and receivables. Strategically, Solesence operates in a competitive, trend-sensitive industry and depends on the success and loyalty of its brand partners, as well as on its ability to keep its technology ahead of rivals and in line with evolving regulations.
If Solesence can sustain its recent revenue momentum, keep margins near recent levels, and gradually convert operating gains into consistent free cash flow, the business could progress from a high-investment growth phase to a more self-sustaining model. Its innovation engine and positioning in mineral-based, “clean” skin defense products align well with long-term consumer trends. However, the path is not without risk: execution on operations, working capital, capital spending, and continued innovation will likely determine whether the company’s recent turnaround becomes a stable, long-term trajectory.
About Solesence, Inc. Common Stock
https://solesence.comSolésence, Inc., formerly Nanophase Technologies Corporation, is a developer and manufacturer of clean, inclusive, mineral-based skincare and makeup products. The company partners with global and indie brands, leveraging its proprietary Active Stress Defense™ technology suite to bring environmental protection beauty products to market.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $14.6M ▼ | $4.15M ▲ | $-1.12M ▼ | -7.67% ▼ | $-0.02 ▼ | $-556K ▼ |
| Q2-2025 | $20.36M ▲ | $3.97M ▲ | $2.67M ▲ | 13.1% ▲ | $0.04 ▲ | $3.37M ▲ |
| Q1-2025 | $14.63M ▲ | $3.13M ▲ | $80K ▲ | 0.55% ▲ | $0 ▲ | $482K ▲ |
| Q4-2024 | $12.57M ▼ | $2.99M ▲ | $-558K ▼ | -4.44% ▼ | $-0.01 ▼ | $5K ▼ |
| Q3-2024 | $16.87M | $2.9M | $3.04M | 18.05% | $0.04 | $3.43M |
What's going well?
R&D spending is steady, and there are no unusual charges distorting results. The company is still investing in its future and hasn't taken on excessive debt.
What's concerning?
Revenue dropped 28%, margins are shrinking, and the company is now losing money after being profitable last quarter. Operating expenses are rising despite falling sales, raising concerns about cost control and business momentum.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $429K ▼ | $53.99M ▼ | $36.76M ▼ | $17.23M ▼ |
| Q2-2025 | $4.11M ▲ | $59.96M ▲ | $41.77M ▼ | $18.19M ▲ |
| Q1-2025 | $1.82M ▲ | $57.02M ▲ | $41.86M ▲ | $15.16M ▲ |
| Q4-2024 | $1.41M ▼ | $50M ▲ | $35.06M ▲ | $14.95M ▼ |
| Q3-2024 | $2.92M | $48.05M | $32.88M | $15.17M |
What's financially strong about this company?
The company has no goodwill or intangibles, so its assets are mostly real and tangible. Debt fell slightly, and working capital needs improved as inventory and receivables declined.
What are the financial risks or weaknesses?
Cash has dropped to a dangerously low level, and the company has a heavy debt load compared to its equity. Retained losses are large, and equity is shrinking, which means the company may need to raise money soon.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.12M ▼ | $-2.51M ▼ | $-418K ▲ | $-750K ▼ | $-3.68M ▼ | $-2.93M ▼ |
| Q2-2025 | $2.67M ▲ | $-654K ▲ | $-1.41M ▼ | $4.35M ▼ | $2.29M ▲ | $-654K ▲ |
| Q1-2025 | $80K ▲ | $-7.22M ▼ | $133K ▲ | $7.5M ▲ | $408K ▲ | $-7.22M ▼ |
| Q4-2024 | $-558K ▼ | $2.19M ▼ | $-2.59M ▼ | $-1.11M ▲ | $-1.52M ▼ | $-404K ▼ |
| Q3-2024 | $3.05M | $4.2M | $-1.4M | $-2.23M | $567K | $2.8M |
What's strong about this company's cash flow?
Receivables and inventory were managed well this quarter, bringing in some cash. No new shares were issued, so existing shareholders weren't diluted.
What are the cash flow concerns?
Operating cash burn jumped to $2.51 million, and free cash flow was deeply negative. Cash reserves are nearly gone, and the company is highly dependent on outside funding to survive.
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
Advanced Materials | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Consumer Products | $0 ▲ | $0 ▲ | $20.00M ▲ | $10.00M ▼ |
Personal Care ingredients | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Solesence | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q3-2024 | Q4-2024 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
NonUS | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Q3 2025 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Solesence, Inc. Common Stock's financial evolution and strategic trajectory over the past five years.
Solesence combines strong recent revenue growth with clear technological differentiation in a high-interest segment of beauty. It has shown that it can swing back to profitability and positive operating cash, while its patent-backed platforms, vertical integration, and regulatory expertise create real barriers to entry. The balance sheet has strengthened with more equity and lower leverage than at its recent peak, and the business model benefits from a flexible, partnership-driven approach to serving multiple brands.
The company’s financial history is short and volatile, with two years of losses, negative retained earnings, and mostly negative free cash flow. It still relies on debt, leases, and external capital to fund its growth and heavy investment. Liquidity is manageable but not abundant, with a lot of working capital tied up in inventory and receivables. Strategically, Solesence operates in a competitive, trend-sensitive industry and depends on the success and loyalty of its brand partners, as well as on its ability to keep its technology ahead of rivals and in line with evolving regulations.
If Solesence can sustain its recent revenue momentum, keep margins near recent levels, and gradually convert operating gains into consistent free cash flow, the business could progress from a high-investment growth phase to a more self-sustaining model. Its innovation engine and positioning in mineral-based, “clean” skin defense products align well with long-term consumer trends. However, the path is not without risk: execution on operations, working capital, capital spending, and continued innovation will likely determine whether the company’s recent turnaround becomes a stable, long-term trajectory.

CEO
Kevin Cureton
Compensation Summary
(Year )
Upcoming Earnings
ETFs Holding This Stock
Summary
Showing Top 3 of 29
Ratings Snapshot
Rating : C-

